The authors discuss the evolution of the purification platform for manufacturing of mAb therapeutics.
Nihal Tugcu
Advertisement
Nihal Tugcu is senior principal scientist at Bioprocess Development, Merck Sharp & Dohme Corp, Kenilworth, New Jersey, USA.
Articles by Nihal Tugcu
Advertisement
Latest Updated Articles
Evolution of the Monoclonal Antibody Purification PlatformPublished: November 1st 2013 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
4
$1.8M RedHill Deal Highlights Growing Worldwide Focus on H. pylori Treatment Access
5
